Cat. #151156
Anti-Rb1 [Rb1 (1F8)]
Cat. #: 151156
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: Retinoblastoma (Rb1)
Class: Monoclonal
Application: IHC ; IF ; IP
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: David Lane
Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-Rb1 [Rb1 (1F8)]
- Alternate name: CD4 Molecule; T-Cell Surface Antigen T4/Leu-3; T-Cell Surface Glycoprotein CD4; CD4 Receptor; CD4 Antigen
- Cancer: Breast cancer;Eye cancer
- Cancers detailed: Breast cancer;Broadly Applicable;Retinoblastoma
- Research fields: Cancer;Cell biology
- Clone: Rb1 (1F8)
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Molecular weight: 105 kDa
- Strain: Balb/c
- Reactivity: Human
- Host: Mouse
- Disease: Breast Cancer
- Application: IHC ; IF ; IP
- Description: The Retinoblastoma protein (Rb) is a transcription factor that controls cell cycle progression (at the G1/S phase transition) through its repression of E2F-mediated transcription. Mutation of the Rb gene is found frequently in human sarcomas, lung, bladder and breast carcinomas and is the molecular basis for hereditary disposition to retinoblastoma.
- Immunogen: Rb-b-galactosidase fusion protein spanning nucleotides 1126-1973 and representing 283 mino acids of Human Rb cDNA
- Isotype: IgG1
- Myeloma used: Sp2/0-Ag14
Target Details
- Target: Retinoblastoma (Rb1)
- Molecular weight: 105 kDa
- Target background: The Retinoblastoma protein (Rb) is a transcription factor that controls cell cycle progression (at the G1/S phase transition) through its repression of E2F-mediated transcription. Mutation of the Rb gene is found frequently in human sarcomas, lung, bladder and breast carcinomas and is the molecular basis for hereditary disposition to retinoblastoma.
Applications
- Application: IHC ; IF ; IP
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
References
- Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates.
- Ragazzon et al. 2014. Eur J Endocrinol. 2014 Feb 4
- 170(3):385-91. PMID: 24347427
- Bandyopadhyay et al. 2007. Aging Cell. 6(4):577-91. PMID: 17578512.
- Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi.
- Lee et al. 2007. Clin Cancer Res. 13(3):832-8. PMID: 17289874.
- Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer.
- Bartkova et al. 2003. J Pathol. 200(2):149-56. PMID: 12754735.
- Deregulation of the RB pathway in human testicular germ cell tumours.
- Brtek et al. 1992. Oncogene. 7(1):101-8. PMID: 1741157.
- Cellular localization and T antigen binding of the retinoblastoma protein.
- Grand et al. 1989. Oncogene. 4(11):1291-8. PMID: 2682458.
- The expression of the retinoblastoma gene product Rb1 in primary and adenovirus-transformed human cells.